If you are not happy with the results below please do another search
Despite all difficulties, over the past 10 years, the largest players in the pharmaceutical market improved their positions. However, some moved far more than others, and they are now creating history. Companies that were at the forefront in 2007 are still the biggest today. Johnson & Johnson has $72 billion in revenue now, $61 billion…
Allergan’s new rosacea treatment Rhofade is getting on formularies—and that means more promotion is on the way. On the drugmaker’s second-quarter earnings call last week, commercial chief Bill Meury told investors that the company had begun advertising the product on Facebook and would “over the next several quarters begin to ramp up other aspects of…
X7 Research ICH-GCP course completion certificate submitted by TransCelerate. Our company’s request to place the certificate was successfully reviewed by TransCelerate BioPharma Inc. Now the certificate is posted on the website of this organization. This means that X7 Research trainings have been received overall recognition along with the projects of other pharmaceutical market players. TransCelerate…
The Ministry of Health suggests that the government determine the monthly rate of financial resources to provide each citizen with medicines and medical services. The Ministry developed an appropriate bill, which is posted on the legal projects portal. Currently, an annual rate is established for each citizen of the Russian Federation, which is approved with…
Which area of the pharmaceutical market is the most attractive in the world? According to Allergan’s CEO, Brent Saunders, this is not a discussion issue. Thanks to a good income in the second quarter, he awarded this title to aesthetic medicine. Allergan is one of the leaders in this area with high growth rates. “It’s…
The fate of the vaccine against hepatitis B, Heplisav-B, from the company Dynavax is now being decided. The FDA request for more detailed information on post-marketing surveillance plans for the vaccine slightly reduced the company’s shares, but both managers and analysts said they remain confident in the approval of the drug. Given the closeness of…